Corbus Pharmaceuticals Holdings, Inc. Common Stock
CRBP US21833P3010
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Altmeyer Anne |
7.25 USD |
1,392 Sold |
10,096 USD |
30/05/2025 | 30/05/2025 |
| Jenkins John Kenneth |
7.35 USD |
2,783 Sold |
20,465 USD |
30/05/2025 | 30/05/2025 |
| Jenkins John Kenneth |
7.35 USD |
2,783 Sold |
20,465 USD |
30/05/2025 | 30/05/2025 |
| Smethurst Dominic CMO |
6.78 USD |
6,393 Sold |
43,330 USD |
06/03/2025 | 06/03/2025 |
| Cohen Yuval CEO |
8.76 USD |
7,134 Sold |
62,465 USD |
14/02/2025 | 14/02/2025 |
| Moran Sean F. CFO |
8.76 USD |
2,792 Sold |
24,446 USD |
14/02/2025 | 14/02/2025 |
| Cohen Yuval CEO |
42.24 USD |
7,179 Sold |
303,219 USD |
14/06/2024 | 18/06/2024 |
| Moran Sean F. CFO |
42.12 USD |
1,958 Sold |
82,479 USD |
14/06/2024 | 18/06/2024 |
| Cohen Yuval CEO |
42.24 USD |
2,322 Sold |
98,074 USD |
14/06/2024 | 18/06/2024 |
| Cohen Yuval CEO |
42.24 USD |
1,770 Sold |
74,759 USD |
14/06/2024 | 18/06/2024 |